PRECIGEN, INC. Goodwill, Acquired During Period
PRECIGEN, INC. (PGEN) reported Goodwill, Acquired During Period of $0 for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-01.
Discontinued › Notes › Intangible Assets › Goodwill and Other
us-gaap:GoodwillAcquiredDuringPeriod · last filed 2019-03-01
- PRECIGEN, INC. goodwill, acquired during period for the quarter ending 2017-12-31 was $0.00.
- PRECIGEN, INC. goodwill, acquired during period for the quarter ending 2017-09-30 was $0.00.
- PRECIGEN, INC. goodwill, acquired during period for the quarter ending 2015-12-31 was -$1.00K, a 100.04% decline year-over-year.
- PRECIGEN, INC. goodwill, acquired during period for the quarter ending 2015-09-30 was $49.27M, a 22.91% decline year-over-year.
- PRECIGEN, INC. goodwill, acquired during period for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- PRECIGEN, INC. goodwill, acquired during period for fiscal 2017 was $4.85M.
- PRECIGEN, INC. goodwill, acquired during period for fiscal 2016 was $0.00, a 100.00% decline from fiscal 2015.
- PRECIGEN, INC. goodwill, acquired during period for fiscal 2015 was $67.40M, a 22.73% decline from fiscal 2014.
| Period end | Goodwill, Acquired During Period 3 month | Goodwill, Acquired During Period 6 month | Goodwill, Acquired During Period 9 month | Goodwill, Acquired During Period 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 10-K · filed 2019-03-01 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $0.00 derived: sum of 2 quarters · filed 2019-03-01 | $4.85M 10-K · filed 2019-03-01 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $4.85M 10-Q · filed 2017-11-09 | ||
| 2017-06-30 | $4.85M 10-Q · filed 2017-08-09 | |||
| 2016-12-31 | $0.00 10-K · filed 2018-03-01 | |||
| 2015-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $49.27M derived: sum of 2 quarters · filed 2017-03-01 | $64.27M derived: sum of 3 quarters · filed 2017-03-01 | $67.40M 10-K · filed 2017-03-01 |
| 2015-09-30 | $49.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $64.27M derived: sum of 2 quarters · filed 2015-11-09 | $67.40M 10-Q · filed 2015-11-09 | $69.69M derived: sum of 4 quarters · filed 2016-02-29 |
| 2015-06-30 | $15.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $18.13M 10-Q · filed 2015-08-10 | $20.41M derived: sum of 3 quarters · filed 2016-02-29 | $84.33M derived: sum of 4 quarters · filed 2016-02-29 |
| 2015-03-31 | $3.13M 10-Q · filed 2015-05-11 | $5.41M derived: sum of 2 quarters · filed 2016-02-29 | $69.33M derived: sum of 3 quarters · filed 2016-02-29 | $64.50M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-12-31 | $2.28M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $66.19M derived: sum of 2 quarters · filed 2016-02-29 | $61.37M derived: sum of 3 quarters · filed 2016-02-29 | $87.24M 10-K · filed 2016-02-29 |
| 2014-09-30 | $63.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | $59.09M derived: sum of 2 quarters · filed 2015-08-10 | $84.95M 10-Q · filed 2014-11-13 | $84.93M derived: sum of 4 quarters · filed 2015-08-10 |
| 2014-06-30 | -$4.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $21.04M 10-Q · filed 2015-08-10 | $21.02M derived: sum of 3 quarters · filed 2015-08-10 | $21.02M derived: sum of 4 quarters · filed 2015-08-10 |
| 2014-03-31 | $25.87M 10-Q · filed 2015-05-11 | $25.84M derived: sum of 2 quarters · filed 2015-05-11 | $25.84M derived: sum of 3 quarters · filed 2015-05-11 | |
| 2013-12-31 | -$23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | -$23.00K derived: sum of 2 quarters · filed 2015-03-02 | $13.82M 10-K · filed 2015-03-02 | |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q/A 6 month · filed 2013-11-07 | $13.85M 10-Q · filed 2013-11-07 | ||
| 2013-06-30 | $13.85M 10-Q/A · filed 2013-10-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |